Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity sees major upside at Wilmington after Spanish bolt-on deal

(Sharecast News) - Canaccord Genuity has reiterated its positive stance on Wilmington following the company's recent acquisition of a Spanish regtech company, saying it sees around 35% upside from the stock's current level. The broker kept a 'buy' rating and 450p target price for the information, data, training and education solutions company, which was trading 1.5% higher at 336p by 1051 BST.

Wilmington announced on 12 August that it was paying £105m to take over Conversia, a Spanish firm focused on the highly regulated data privacy sector.

According to Canaccord Genuity, the acquisition has "multiple attractions", including the potential to expand Wilmington's total addressable market (TAM) and recurring revenue share within the core area of governance, risk and compliance (GRC) training.

Meanwhile, with the Spanish firm said to be growing at a double-digit rating at time of expanding margins, the financials to Wilmington look "favourable", the broker said.

"Conversia looks like an attractive asset, well-aligned with Wilmington's 'must-have' GRC training services, as well as the emerging RegTech platform, adding a market leading software and services portfolio with high retention rates (>90%) and recurring revenues (~72%) to the group," Canaccord said.

"With completion subject to Foreign Direct Investment clearance in Spain (estimated in Wilmington's 2Q26), we leave our forecasts unchanged, but expect Conversia to be earnings enhancing in the first full year of ownership."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.